Multiple predicted inflammatory and signaling proteins

The term "Multiple predicted inflammatory and signaling proteins" refers to a heterogeneous group of biological molecules rather than a single, well-defined therapeutic target. This designation is typically used in the context of large-scale omics studies, such as proteomics or transcriptomics, to describe a set of proteins that show altered expression or activity in response to a stimulus or disease state (Kustrimovic et al., 2019, Frontiers in Immunology). Because it encompasses various functional classes—such as cytokines, chemokines, intracellular signaling kinases, and transcription factors—it does not possess a singular mechanism of action or a specific pharmacological profile. In drug discovery, a target must be a discrete molecular entity to allow for the development of specific ligands and the assessment of safety and efficacy (Schenone et al., 2013, Nature Chemical Biology). Targeting a broad and ill-defined category of proteins would likely result in significant off-target effects and unpredictable systemic toxicity (Santos et al., 2017, Nature Reviews Drug Discovery). Consequently, this entry is classified as incorrect for structured target annotation, as it represents a descriptive category rather than a unique, druggable receptor or enzyme.

Not applicable